|
Intellectual Property Portfolio
Motac personnel have extensive practical
experience and technical know-how
accumulated over many years working with the
in vitro and in vivo models
offered. In addition, Motac personnel
include several prominent international
authorities in the fields of movement
disorders and neurodegenerative conditions.
One of the things that makes Motac unique is
its ability to offer access to the best
models of these conditions available,
underpinned by first-class scientific
understanding, yet offered in a commercial
environment with an emphasis on quality and
timeliness. In addition, Motac possesses a
portfolio of world-wide patents and patent
applications based around the treatment of
movement disorders. Those in the public
domain include:
·
μ (mu) opioid receptor antagonists for the
treatment of dyskinesias
·
histamine H3 receptor agonists
for the treatment of dyskinesias
·
mGluR5 receptor antagonists for
the treatment of Parkinson's Disease
·
5-HT1A receptor agonists for
extending "on-time" and alleviating motor
fluctuations in the treatment of Parkinson's
disease
·
topiramate and related compounds for the
treatment of dyskinesias
·
2,3-benzodiazepines for the treatment of
dyskinesias
Motac is actively seeking partners who
possess compounds in these classes in order
to develop new drugs for movement disorders
based around these targets.
|
